Immunological Insights and Vaccine Development for SARS-CoV-2

The global response to SARS-CoV-2 has generated an extensive body of work elucidating both the innate and adaptive immune mechanisms that determine disease outcome and vaccine efficacy. Central to protective immunity are neutralising antibodies directed against the spike glycoprotein, particularly its receptor-binding domain, which block viral entry into host cells. Parallel efforts have characterised T-cell responses to structural and non-structural antigens, revealing key correlates of long-term immune memory. High-throughput epitope mapping and proteome microarrays have defined immunodominant regions across the viral proteome, guiding subunit and peptide vaccine design. Modern vaccine platforms—including mRNA formulations, viral vectors, protein subunits and peptide-based constructs delivered via microneedle arrays—have demonstrated robust immunogenicity and adaptability to emerging variants. Together, these insights underpin next-generation vaccine strategies with global application, from dose optimisation and booster regimens to thermostable delivery systems that enhance equitable access.

Research from Nature Portfolio

Recent studies have precisely delineated linear B-cell epitopes on the SARS-CoV-2 spike protein that elicit potent neutralisation. One investigation identified two immunodominant regions—one adjacent to the receptor-binding domain and one at the fusion peptide—demonstrating that antibody depletion targeting these sites significantly reduces viral neutralisation capacity. Complementing this, comprehensive proteome microarray analyses of convalescent sera have mapped IgG and IgM responses across eighteen viral proteins, confirming the prominence of spike S1 and nucleocapsid antigens and uncovering additional targets such as ORF9b and NSP5. Further work has validated a multiplexed antigen microarray capable of distinguishing pre-pandemic controls from infected individuals with near-perfect accuracy, improving both serodiagnostic performance and understanding of antigen combinations required for broad antibody detection. Collectively, these efforts provide a refined blueprint for antigen selection in both diagnostic assays and vaccine formulations.

Immunological Insights and Vaccine Development for SARS-CoV-2 publication trend

The graph below shows the total number of articles in immunological insights and vaccine development for sars-cov-2 across all publications each year (not limited to Nature Index journals).

Technical terms

Epitope: A contiguous amino-acid sequence on an antigen recognised specifically by an antibody or T-cell receptor.

Neutralising antibody: An antibody that binds to a pathogen and directly prevents infection of host cells.

Proteome microarray: A high-throughput platform displaying an organism’s full complement of proteins or peptides to profile antibody–antigen interactions.

Receptor-binding domain (RBD): The region of a viral spike protein that engages host-cell receptors to facilitate viral entry.

Dissolvable microneedle array: A patch of microscopic needles that painlessly deliver vaccine components into the skin and dissolve upon application.

mRNA vaccine: A vaccine modality utilizing messenger RNA encoding antigenic proteins to elicit a protective immune response.

References

1. A Newly Identified Spike Protein Targeted Linear B‐Cell Epitope Based Dissolvable Microneedle Array Successfully Eliciting Neutralizing Activities against SARS‐CoV‐2 Wild‐Type Strain in Mice. Advanced Science (2023).
2. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nature Communications (2020).
3. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. Nature Communications (2020).
4. Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray. Nature Communications (2021).
5. Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations. International Journal of Molecular Sciences (2023).
6. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses (2020).